Skip to main content
Industry Use Case

AI for Pharma - Without Your Clinical Data and Drug Discovery IP Leaving the Building

Pharmaceutical companies and life sciences organizations are adopting AI at every stage - from early drug discovery to clinical trial operations to regulatory submissions. But every AI prompt risks exposing proprietary compound data, protected health information, and trade secrets to external model providers. Shield keeps that data on your machines, within your GxP-validated environment, under your control.

Quick Answer

Shield for Pharma & Life Sciences is a local desktop application that stops clinical trial data, drug discovery IP, and regulatory submission documents from ever leaving your organization's computers - before that data reaches ChatGPT, Claude, Copilot, or any AI model. It runs on your existing machines, requires no cloud infrastructure, and helps pharmaceutical companies, biotechs, CROs, and medical device manufacturers meet FDA 21 CFR Part 11, GxP, HIPAA, GDPR, and EMA requirements without changing how scientists, clinicians, and regulatory professionals use AI tools.

FDA 21 CFR Part 11
Electronic records and signatures regulation
Part 11 establishes the criteria under which the FDA considers electronic records and signatures to be trustworthy, reliable, and equivalent to paper records. It applies to records created, modified, maintained, archived, retrieved, or transmitted under any FDA predicate rules - including GLP (21 CFR Part 58), GMP (21 CFR Parts 210-211), and GCP. When clinical data, batch records, or regulatory correspondence is pasted into an external AI tool, the electronic record leaves your validated, Part 11-compliant environment.
Source: 21 CFR Part 11; FDA Guidance for Industry, August 2003
5+ Frameworks
Regulations governing pharma data in AI use
Pharmaceutical and life sciences companies must navigate FDA 21 CFR Part 11, HIPAA (for clinical data involving US patients), GDPR (for EU patient data and employee information), GxP quality regulations (GLP, GCP, GMP), and EMA guidelines for European marketing authorization. State-level data privacy laws and international frameworks like Japan's APPI and China's PIPL add further requirements for multi-region trials and global pharmacovigilance operations.
Multiple statutes - FDA, HIPAA, GDPR, EMA, APPI, PIPL, state laws
Zero
Proprietary data leaves your network
Shield runs locally on your organization's machines - no cloud processing, no vendor data access. Clinical trial data, compound structures, synthetic routes, stability data, and regulatory correspondence never reach external AI providers. The redaction mapping stays on your machine, inside your network boundary - consistent with GxP data integrity requirements and trade secret protections under the DTSA.
Shield operates within your network boundary

Shield for Pharma is a local desktop application that redacts regulated pharmaceutical data - clinical trial identifiers, compound data, batch records, and regulatory correspondence - before it reaches external AI providers, while preserving the AI's ability to generate useful responses.

Click through each scenario to see what regulated data is caught - and how the AI still gets everything it needs to be useful.

Scenario
Clinical Research Coordinator Drafting Trial Reports with AI

A clinical research coordinator at a mid-size biotech uses an AI assistant to draft patient narratives for a Phase II oncology trial, pasting patient identifiers, adverse event details, and site information into the prompt.

What the user pastes (raw)
Draft a patient narrative for Subject 14-0873 (screening ID SCR-2025-4192) in the PRO-ONC-202 trial. Patient demographics: 62-year-old female, diagnosed Stage IIIB NSCLC (EGFR exon 19 deletion). Enrollment date: March 14, 2025 at Site 07 - Oncology Associates of North Texas (PI: Dr. Rebecca Hartman, NPI 1588664328). Treatment arm: Arm B (pembrolizumab 200mg + PRO-202 450mg Q3W). Adverse event: Grade 3 transaminitis (ALT 320 U/L, AST 275 U/L) on Cycle 3 Day 15. Concomitant meds: atorvastatin 20mg, lisinopril 10mg, metformin 500mg BID. SAE reported to IRB #2025-03-118. Subject contact: 555-0142, 1042 Magnolia Ct, Durham NC 27703.
Shield Redacts on Your Machine
What the AI receives (clean)
Draft a patient narrative for Subject [SUBJECT_ID] (screening ID [SCREENING_ID]) in the [TRIAL_ID] trial. Patient demographics: [AGE]-year-old [SEX], diagnosed [CONDITION] ([BIOMARKER]). Enrollment date: [DATE] at [SITE_NAME] (PI: [PI_NAME], NPI [NPI]). Treatment arm: [ARM_DESCRIPTION]. Adverse event: [AE_GRADE] [AE_DESCRIPTION] on [CYCLE_DAY]. Concomitant meds: [MED_LIST]. SAE reported to IRB #[IRB_REF]. Subject contact: [PHONE], [ADDRESS].
Detected & Redacted (9 items)
PHI - ID Subject ID
PII - ID Screening ID
PHI - Name PI Name
PII - ID NPI Number
PII - Phone Subject Phone
PII - Address Subject Address
PHI - Medical Diagnosis + Biomarker
PHI - Medical Lab Results
Sensitive - Trial Trial Protocol ID

How Shield Protects Pharma Data is a local gateway architecture: regulated data is intercepted and redacted on your machine, and only the clean prompt leaves your network.

Clinical data, compound structures, and regulatory documents stay inside your GxP-validated network boundary. The AI provider never sees patient identifiers, proprietary structures, or trade secrets.

Pharma / BiotechELN / LIMS / CTMSprompt + clinical data / IPShieldLocal Redaction Proxysubject IDs > [SUBJECT] . NPI > [NPI]clean prompt onlyAI ProviderChatGPT / Claude / etc.AI responserehydrate locallyresponse with data restoredYour GxP-Validated NetworkExternal Internet

Regulatory Framework Mapping: Shield supports compliance with the frameworks governing pharmaceutical data - FDA 21 CFR Part 11 for electronic records, HIPAA for clinical trial PHI, GxP for quality systems, GDPR for EU patient data, and EMA guidelines for marketing authorization.

The table below maps each framework to what it requires and how Shield helps meet those requirements - without changing how your scientists and regulatory professionals use AI.

1
FDA 21 CFR Part 11
Scope
Electronic records and signatures for FDA-regulated activities
Requirement
Electronic records must be trustworthy, reliable, and equivalent to paper records. Systems must include validation, audit trails, authority checks, and device checks. Electronic signatures must be unique to one individual.
How Shield Helps
Prevents regulated electronic records - clinical data, batch records, CMC information - from leaving your Part 11-validated environment when users paste them into external AI tools. Data stays within your controlled, validated systems.
2
HIPAA
Scope
Protected health information in clinical research (US)
Requirement
Covered entities and business associates must implement safeguards for PHI, including access controls, audit controls, and transmission security. Clinical trial data containing PHI is subject to HIPAA protections.
How Shield Helps
Redacts 18 HIPAA identifiers - names, dates, phone numbers, SSNs, medical record numbers, and more - from clinical data before it reaches external AI providers. Operates as a technical safeguard within your covered entity's environment.
3
GxP (GLP/GCP/GMP)
Scope
Quality systems for laboratory, clinical, and manufacturing operations
Requirement
Data integrity under ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available. Audit trails must document who did what and when.
How Shield Helps
Maintains GxP data integrity by preventing regulated data from entering uncontrolled external systems. Recognizes GxP data patterns - batch numbers, analytical results, equipment IDs - and redacts them, preserving the chain of custody within your quality system.
4
GDPR
Scope
Personal data of EU subjects in clinical trials
Requirement
Data minimization, purpose limitation, and appropriate technical measures for personal data. Clinical trial data from EU subjects is personal data under GDPR and subject to territorial scope (Art. 3).
How Shield Helps
Enforces data minimization at the network edge - personal data from EU trial subjects is redacted before transmission. Because Shield runs locally, data from EU sites remains subject to GDPR jurisdictional requirements without cross-border data transfer concerns.
5
EMA Guidelines
Scope
Marketing authorization and clinical data for EU medicines
Requirement
EMA requires compliance with GCP (ICH E6 R2) and data integrity standards for clinical trial data supporting marketing authorization applications in the European Union.
How Shield Helps
Supports ICH E6 R2 requirements for data confidentiality and integrity by ensuring that clinical trial data used in regulatory submissions never transits uncontrolled external systems, preserving the reliability of evidence supporting your marketing authorization.

Frequently Asked Questions

Common questions from pharmaceutical, biotech, and life sciences organizations evaluating Shield for regulated AI use.

Shield operates at the data protection layer, not the records management layer. Part 11 governs how electronic records and signatures are created, maintained, and archived within validated systems. Shield prevents the records themselves from ever leaving your controlled environment - which supports Part 11's requirement that electronic records remain trustworthy, reliable, and confidential. When a researcher pastes clinical data into an AI prompt, Shield redacts that data before it reaches an external AI provider, keeping the original electronic record within your Part 11-validated systems. Shield does not replace your electronic document management system (EDMS) or quality management system (QMS) - it adds a protection layer that prevents regulated data from bypassing those systems entirely.
GxP regulations - including GLP (Good Laboratory Practice), GCP (Good Clinical Practice), and GMP (Good Manufacturing Practice) - require that data be attributable, legible, contemporaneous, original, and accurate (the ALCOA+ principles). When regulated data is pasted into an AI tool that sits outside your validated GxP environment, the chain of custody breaks. Shield prevents that break by intercepting GxP-governed data before it crosses the network boundary. Shield's redaction engine can be configured with filter packs that recognize GxP data patterns - batch records, stability study results, analytical test data, and equipment qualification records - and redact them before they reach external AI models.
Shield operates at the network proxy layer, not inside specific applications. It sits between your AI client and the model provider, inspecting outbound requests regardless of which tool the user copied data from. This means Shield works with any ELN (Benchling, IDBS E-WorkBook, PerkinElmer Signals), any LIMS (LabVantage, STARLIMS, Thermo Fisher SampleManager), and any document management system - with zero integration work. As long as the data flows through Shield's local proxy on its way to an AI provider, it's caught and redacted.
Many pharmaceutical companies and biotechs share clinical data with CROs for monitoring, data management, and statistical analysis. When CRO personnel or sponsor staff use AI tools to analyze or summarize trial data - patient narratives, safety reports, statistical outputs - Shield can be deployed on each machine that handles that data. For sponsor-CRO collaboration, Shield's consistent policy enforcement ensures the same redaction rules apply regardless of whether the user is a sponsor employee, a CRO clinical research associate, or a third-party biostatistician. Each deployment runs locally; no data flows through Purfect Labs servers.
Yes. Pharmaceutical manufacturing involves highly proprietary process data - synthetic routes, formulation compositions, critical process parameters, and equipment configurations - that represent years of R&D investment and are protected as trade secrets. When manufacturing scientists or quality engineers use AI tools to troubleshoot process deviations, optimize yields, or draft deviation reports, Shield redacts batch numbers, equipment IDs, process parameters, and formulation details before those details reach external AI providers. This protects your manufacturing IP under the Defend Trade Secrets Act (DTSA) and equivalent international frameworks.
Pharmaceutical development is inherently global - a single clinical trial may enroll patients across the US, EU, and Asia-Pacific. Shield can be configured with jurisdiction-aware rules: for US sites, apply HIPAA protections to protected health information; for EU sites, apply GDPR data minimization to personal data; for multi-region trials, both frameworks apply. Because Shield runs locally, data from EU sites stays subject to GDPR territorial scope requirements. No data is centralized or processed by Purfect Labs - each deployment independently enforces the policies you configure for its jurisdiction.

Related Articles

Explore related Shield industry guides and technical deep dives.

Shield for Healthcare AI
Protect PHI under HIPAA - clinical notes, billing data, and patient communications.
Shield for Financial Services
Keep account numbers, SSNs, and portfolio data safe under PCI DSS and GLBA.
AI Governance Frameworks
NIST, ISO 42001, EU AI Act, and OWASP - compare frameworks and assess your maturity.

Ready to Protect Your Pharma Data?

Shield installs in minutes. Your clinical trial data, drug discovery IP, and regulatory documents stay on your organization's machines - where FDA 21 CFR Part 11, GxP, and your intellectual property strategy expect them to be.

Talk to Our Team How Shield Works

Last updated: August 1, 2026